Eye2Gene, an artificial intelligence (AI) initiative, and Heidelberg Engineering, a leader in ophthalmic imaging and data technologies, have entered into a collaborative partnership, which was announced at the ARVO 2024 meeting. 

“By combining the power of Heidelberg image quality and artificial intelligence, we are poised to empower eye care professionals with comprehensive insights into genetic diagnosis of inherited retinal disease (IRD), ultimately enhancing treatment outcomes and improving patient care,” Arianna Schoess Vargas, managing director of Heidelberg Engineering, said in a news release. A demonstration to convey the capabilities of the partnership showcased the integration of Eye2Gene’s AI algorithm for the prediction of IRD genes using Spectralis BluePeak Autofluorescence, cSLO Infrared, and OCT images, with HEYEX 2’s Heidelberg AppWay. The combination will enable researchers to uncover how images acquired with the Spectralis can be interrogated by Eye2Gene to predict which gene is causing the inherited disease, offering a glimpse into the future of precision medicine in ophthalmology.